#compounding-pharmacies

#compounding-pharmacies

The rising popularity of Ozempic alternatives continues despite expected supply increases due to significant pricing differences.

The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.

Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.

Compounded versions of Novo Nordisk's Wegovy and Ozempic must halt production following a federal court ruling upholding FDA's assessed resolution of shortages.

Millions of Americans on injectable weight loss medications face financial uncertainty as affordable compounded versions are being phased out.

The FDA has resolved the tirzepatide shortage, improving access to brand-name drugs but disrupting the compounded medication market.

Demand for Ozempic and its alternatives has led to compounded versions, but brand manufacturers are actively trying to eliminate this competition.

FDA warns about safety issues with compounded weight-loss drugs as pharmaceutical companies fight against them amid legal battles and differing interests.